17,261 trials
Relapsed/Refractory Multiple Myeloma
Primary: The Evaluation of Progression Free Survival (PFS) in Subjects With Relapsed or Refractory Multiple Myeloma and Renal Impairment Treated With Daratumumab and…
Advanced Cancer · Melanoma · Non-Small Cell Lung Cancer
Primary: Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and Deaths — 1; 1; 0; 7 Participants
Melanoma
Primary: Number of Participants With Dose-limiting Toxicities. — 0; 3 Participants
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · Vulvar Dysplasia · Vulvar Intraepithelial Neoplasia (VIN)
Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…
Hypoglycemia
Primary: Outpatient Phase: Incidence Rate of Hypoglycemia During and After Moderate to High Intensity Aerobic Exercise. — 0.12; 0.39; 0.16; 0.24 events/session — p=0.0002
Perinatal Depression · Post Partum Depression · Depression, Postpartum
Primary: Mean Threat Processing Bias During Visual Dot-probe Paradigm Over Time — -0.57; 36.92; -9.04; -42.35 attention bias in milliseconds — p=0.160
Narcolepsy · Cataplexy Narcolepsy · Excessive Sleepiness
Primary: Change From Baseline in the Weekly Average Total Number of Cataplexy Attacks — 13.0; -0.28 weekly cataplexy attacks — p=<0.001
Rheumatoid Arthritis
Primary: Arms 1 & 2: Assess Camera-specific Precision of TUV — 0.159; 0.067; 0.091; 0.124 Pixel intensity
Metastatic Breast Cancer · Breast Carcinoma · HER-2 Positive Breast Cancer
Primary: Maximum Tolerated Dose of Ruxolitinib in Combination With Trastuzumab (Phase I) — 25 milligrams
Primary Myelofibrosis · Anemia
Primary: The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period — 3; 2; 2; 10 Participants
Cardiovascular Disease
Primary: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 — -66.91; -93.78; -97.53; -96.89 Percentage Change in Lp(a) — p=<0.001
Chronic Spinal Cord Injury
Primary: Incidence of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 5; 6 Participants
Stage 0 Breast Cancer AJCC v6 and v7 · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Primary: Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP — 44.0; 58.2; 37.5; 23.1 percentage of participants
Prostate Cancer
Primary: Relative Expression of U19 Gene in Tumor From Prostate Gland During First Off-cycle. — 0.24; 0.28 Relative expression